{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:59:54Z","timestamp":1793134794779,"version":"4.5.0"},"reference-count":114,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T00:00:00Z","timestamp":1585526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UID\/MULTI\/04326\/2019"],"award-info":[{"award-number":["UID\/MULTI\/04326\/2019"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PTDC\/MAR-BIO\/4132\/2014"],"award-info":[{"award-number":["PTDC\/MAR-BIO\/4132\/2014"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UID\/QUI\/00313\/2019"],"award-info":[{"award-number":["UID\/QUI\/00313\/2019"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"name":"PTDC\/MAR-BIO\/4132\/2014","award":["SFRH\/BD\/140249\/2018"],"award-info":[{"award-number":["SFRH\/BD\/140249\/2018"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Toxoplasmosis is an infectious disease with paramount impact worldwide, affecting many vulnerable populations and representing a significant matter of concern. Current therapies used against toxoplasmosis are based essentially on old chemotypes, which fail in providing a definitive cure for the disease, placing the most sensitive populations at risk for irreversible damage in vital organs, culminating in death in the most serious cases. Antimalarial drugs have been shown to possess key features for drug repurposing, finding application in the treatment of other parasite-borne illnesses, including toxoplasmosis. Antimalarials provide the most effective therapeutic solutions against toxoplasmosis and make up for the majority of currently available antitoxoplasmic drugs. Additionally, other antiplasmodial drugs have been scrutinized and many promising candidates have emanated in recent developments. Available data demonstrate that it is worthwhile to explore the activity of classical and most recent antimalarial chemotypes, such as quinolines, endoperoxides, pyrazolo[1,5-a]pyrimidines, and nature-derived peptide-based parasiticidal agents, in the context of toxoplasmosis chemotherapy, in the quest for encountering more effective and safer tools for toxoplasmosis control or eradication.<\/jats:p>","DOI":"10.3390\/molecules25071574","type":"journal-article","created":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T05:55:16Z","timestamp":1585893316000},"page":"1574","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Antimalarial Agents as Therapeutic Tools Against Toxoplasmosis\u2014A Short Bridge between Two Distant Illnesses"],"prefix":"10.3390","volume":"25","author":[{"given":"Alina","family":"Secrieru","sequence":"first","affiliation":[{"name":"Center of Marine Sciences, CCMAR, Gambelas Campus, University of Algarve, UAlg, 8005-139 Faro, Portugal"},{"name":"Department of Chemistry and Pharmacy, Faculty of Sciences and Technology, FCT, Gambelas Campus, University of Algarve, UAlg, 8005-139 Faro, Portugal"},{"name":"Department of Chemistry, University of Liverpool, Liverpool L69 7ZD, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00eas C. C.","family":"Costa","sequence":"additional","affiliation":[{"name":"Center of Marine Sciences, CCMAR, Gambelas Campus, University of Algarve, UAlg, 8005-139 Faro, Portugal"},{"name":"Department of Chemistry and Pharmacy, Faculty of Sciences and Technology, FCT, Gambelas Campus, University of Algarve, UAlg, 8005-139 Faro, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"O'Neill","sequence":"additional","affiliation":[{"name":"Department of Chemistry, University of Liverpool, Liverpool L69 7ZD, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9447-2855","authenticated-orcid":false,"given":"Maria L. S.","family":"Cristiano","sequence":"additional","affiliation":[{"name":"Center of Marine Sciences, CCMAR, Gambelas Campus, University of Algarve, UAlg, 8005-139 Faro, Portugal"},{"name":"Department of Chemistry and Pharmacy, Faculty of Sciences and Technology, FCT, Gambelas Campus, University of Algarve, UAlg, 8005-139 Faro, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,3,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/nature06536","article-title":"Global trends in emerging infectious diseases","volume":"451","author":"Jones","year":"2008","journal-title":"Nature"},{"key":"ref_2","unstructured":"WHO (2004). Guidelines for Drinking-water Quality, World Health Organization. [3rd ed.]."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1179\/2047773213Y.0000000094","article-title":"Antibiotics for human toxoplasmosis: A systematic review of randomized trials","volume":"107","author":"Rajapakse","year":"2013","journal-title":"Pathog. Glob. Health"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Chimelli, L. (2011). A Morphological Approach to the Diagnosis of Protozoal Infections of the Central Nervous System. Patholog. Res. Int., 2011.","DOI":"10.4061\/2011\/290853"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Seeber, F., and Steinfelder, S. (2016). Recent advances in understanding apicomplexan parasites. F1000Research, 5.","DOI":"10.12688\/f1000research.7924.1"},{"key":"ref_6","unstructured":"WHO (2015). Guidelines for the Treatment of Malaria, World Health Organization. [3rd ed.]."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.cell.2016.07.055","article-title":"Malaria: Biology and Disease","volume":"167","author":"Cowman","year":"2016","journal-title":"Cell"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.phrs.2016.11.012","article-title":"Artemisinin and its derivatives in treating protozoan infections beyond malaria","volume":"117","author":"Loo","year":"2017","journal-title":"Pharm. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s40268-017-0206-8","article-title":"Adverse Event Profile of Pyrimethamine-Based Therapy in Toxoplasmosis: A Systematic Review","volume":"17","author":"Goodwin","year":"2017","journal-title":"Drugs R D"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"300","DOI":"10.12968\/coan.2019.24.6.300","article-title":"Toxoplasma gondii \u2013 the facts","volume":"24","author":"Castro","year":"2019","journal-title":"Companion Anim."},{"key":"ref_11","first-page":"435","article-title":"Toxoplasmosis in Germany\u2014epidemiology, diagnosis, risk factors, and treatment","volume":"116","author":"Pleyer","year":"2019","journal-title":"Dtsch. Arztebl. Int."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/S0140-6736(04)16412-X","article-title":"Toxoplasmosis","volume":"363","author":"Montoya","year":"2004","journal-title":"Lancet."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1046\/j.1469-0691.2002.00485.x","article-title":"Toxoplasma gondii: Transmission, diagnosis, and prevention","volume":"8","author":"Hill","year":"2002","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1891\/0730-0832.34.5.274","article-title":"Congenital toxoplasmosis: A review","volume":"34","author":"Hampton","year":"2015","journal-title":"Neonatal Netw."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Saso, A., Bamford, A., Grewal, K., Noori, M., Hatcher, J., D\u2019arco, F., Guy, E., and Lyall, H. (2020). Fifteen minute consultation: Management of the infant born to a mother with toxoplasmosis in pregnancy. Arch. Dis Child. Educ Pract Ed., 1\u20138.","DOI":"10.1136\/archdischild-2018-316603"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jpsychires.2018.12.016","article-title":"Latent toxoplasmosis and psychiatric symptoms \u2013 A role of tryptophan metabolism?","volume":"110","author":"Mors","year":"2019","journal-title":"J. Psychiatr. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1007\/s00436-017-5478-y","article-title":"Toxoplasma gondii and schizophrenia: A review of published RCTs","volume":"116","author":"Chorlton","year":"2017","journal-title":"Parasitol. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.17219\/acem\/61435","article-title":"Relationship between toxoplasmosis and schizophrenia: A review","volume":"26","author":"Fuglewicz","year":"2017","journal-title":"Adv. Clin. Exp. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"7161","DOI":"10.1128\/AAC.02009-15","article-title":"Clinically Available Medicines Demonstrating Anti-Toxoplasma Activity","volume":"59","author":"Neville","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_20","first-page":"212","article-title":"Latent Toxoplasmosis: Host-parasite interaction and psychopathology","volume":"2019","year":"2019","journal-title":"Evol. Med. Public Heal."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Montazeri, M., Sharif, M., Sarvi, S., Mehrzadi, S., Ahmadpour, E., and Daryani, A. (2017). A systematic review of in vitro and in vivo activities of anti-Toxoplasma drugs and compounds (2006\u20132016). Front. Microbiol., 8.","DOI":"10.3389\/fmicb.2017.00025"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0138204","article-title":"A systematic review and meta-analysis of the efficacy of anti-Toxoplasma gondii medicines in humans","volume":"10","author":"Wei","year":"2015","journal-title":"PLoS ONE"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3201\/eid2504.181689","article-title":"Combination of clindamycin and azithromycin as alternative treatment for Toxoplasma gondii encephalitis","volume":"25","author":"Shiojiri","year":"2019","journal-title":"Emerg. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Maldonado, Y.A., Read, J.S., Byington, C.L., Barnett, E.D., Davies, H.D., Edwards, K.M., Lynfield, R., Munoz, F.M., Nolt, D., and Nyquist, A.C. (2017). Diagnosis, treatment, and prevention of congenital toxoplasmosis in the United States. Pediatrics, 139.","DOI":"10.1542\/peds.2016-3860"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1016\/j.cub.2019.07.019","article-title":"Multiple Independent Origins of Apicomplexan-Like Parasites","volume":"29","author":"Mathur","year":"2019","journal-title":"Curr. Biol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Amberg-Johnson, K., and Yeh, E. (2019). Host Cell Metabolism Contributes to Delayed-Death Kinetics of Apicoplast Inhibitors in Toxoplasma gondii. Antimicrob Agents Chemother., 63.","DOI":"10.1128\/AAC.01646-18"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.2298\/JSC150430063O","article-title":"Tetraoxanes as inhibitors of apicomplexan parasites Plasmodium falciparum and Toxoplasma gondii and anti-cancer molecules","volume":"80","author":"Opsenica","year":"2015","journal-title":"J. Serbian Chem. Soc."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2147\/DDDT.S60973","article-title":"Drugs in development for toxoplasmosis: Advances, challenges, and current status","volume":"11","author":"Alday","year":"2017","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.str.2015.02.011","article-title":"Structure of prolyl-tRNA synthetase-halofuginone complex provides basis for development of drugs against malaria and toxoplasmosis","volume":"23","author":"Jain","year":"2015","journal-title":"Structure"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5951","DOI":"10.1039\/C6OB01083K","article-title":"Enol ethers as carbonyl surrogates in a modification of the Povarov synthesis of 3-aryl quinolines and their anti-Toxoplasma activity","volume":"14","author":"Brown","year":"2016","journal-title":"Org. Biomol. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.01640-17","article-title":"Discovery of New Inhibitors of Toxoplasma Gondii via the Pathogen Box","volume":"62","author":"Spalenka","year":"2018","journal-title":"Antimicrob Agents Chemother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1080\/00325481.2019.1655258","article-title":"Perspective on Current and Emerging Drugs in the Treatment of Acute and Chronic Toxoplasmosis","volume":"131","author":"Lapinskas","year":"2019","journal-title":"Postgrad. Med."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Konstantinovic, N., Guegan, H., St\u00e4jner, T., Belaz, S., and Robert-Gangneux, F. (2019). Treatment of Toxoplasmosis: Current Options and Future Perspectives. Food Waterborne Parasitol., 15.","DOI":"10.1016\/j.fawpar.2019.e00036"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"111711","DOI":"10.1016\/j.ejmech.2019.111711","article-title":"Recent Progress on Anti-Toxoplasma Drugs Discovery: Design, Synthesis and Screening","volume":"183","author":"Deng","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Philip, J., and Rosenthal, M.D. (2001). The History of Antimalarial Drugs. Antimalarial Chemotherapy, Humana Press.","DOI":"10.1385\/1592591116"},{"key":"ref_36","unstructured":"Peters, W., and Rogers, W.H.G. (1984). Quinine and Quinine Analogues. Antimalarial Drugs II: Current Antimalarials and New Drug Developments, Springer."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0163-7258(97)00084-3","article-title":"4-Aminoquinolines-Past, Present, and Future: A Chemical Perspective","volume":"77","author":"Bray","year":"1998","journal-title":"Pharmacol. Ther."},{"key":"ref_38","unstructured":"Attanasi, O., Merino, P., and Spinelli, D. (2018). Quinolones for Applications in Medicinal Chemistry: Synthesis and Structure. Targets in Heterocyclic Systems, Societ\u00e0 Chimica Italiana."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"107756","DOI":"10.1016\/j.exppara.2019.107756","article-title":"Biological Evaluation of Newly Synthesized Quinoline\u2013Based Compound PPQ-8 in Acute and Chronic Toxoplasmosis: An Experimental Study","volume":"206","author":"Elgawad","year":"2019","journal-title":"Exp. Parasitol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1021\/acsinfecdis.8b00133","article-title":"Targeted Structure-Activity Analysis of Endochin-like Quinolones Reveals Potent Qi and Qo Site Inhibitors of Toxoplasma gondii and Plasmodium falciparum Cytochrome bc1 and Identifies ELQ-400 as a Remarkably Effective Compound against Acute Experimental Toxoplasmosis\u201d","volume":"4","author":"McConnell","year":"2018","journal-title":"ACS Infect. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.01866-16","article-title":"Genetic Evidence for Cytochrome b Qi Site Inhibition by 4(1H)-Quinolone-3- Diarylethers and Antimycin in Toxoplasma gondii","volume":"61","author":"Alday","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"15936","DOI":"10.1073\/pnas.1208069109","article-title":"Endochin-like Quinolones Are Highly Efficacious against Acute and Latent Experimental Toxoplasmosis","volume":"109","author":"Doggett","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2018.01.039","article-title":"Antiplasmodial and Antimalarial Activities of Quinolone Derivatives: An Overview","volume":"146","author":"Fan","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/cber.19480810103","article-title":"\u00dcber Einen Neuen, Gegen Vogelmalaria Wirksamen Verbindungstypus","volume":"81","author":"Salzer","year":"1948","journal-title":"Chem. Ber."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Casey, A.C. (1974). Synthesis of Some 4-Quinolones and Related Structures for Evaluation as Potential Antimalarial Agents, University of Bridgeport.","DOI":"10.21236\/ADA007248"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.exppara.2007.10.016","article-title":"Antimalarial Quinolones: Synthesis, Potency, and Mechanistic Studies","volume":"118","author":"Winter","year":"2008","journal-title":"Exp. Parasitol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1186\/1475-2875-13-339","article-title":"Recent Progress in the Development of Anti-Malarial Quinolones","volume":"13","author":"Beteck","year":"2014","journal-title":"Malar. J."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1021\/bi802216h","article-title":"Across Membrane Communication between the Qo and Qi Active Sites of Cytochrome Bc1","volume":"48","author":"Cooley","year":"2009","journal-title":"Biochemistry"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1128\/mr.54.2.101-129.1990","article-title":"Cytochrome Bc1 Complexes of Microorganisms","volume":"54","author":"Trumpower","year":"1990","journal-title":"Microbiol. Rev."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1590\/0074-02760160417","article-title":"Insights into Cytochrome Bc1 Complex Binding Mode of Antimalarial 2-Hydroxy-1,4-Naphthoquinones through Molecular Modelling","volume":"112","author":"Sodero","year":"2017","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1021\/acsinfecdis.7b00062","article-title":"Alkoxycarbonate Ester Prodrugs of Preclinical Drug Candidate ELQ-300 for Prophylaxis and Treatment of Malaria","volume":"3","author":"Frueh","year":"2017","journal-title":"ACS Infect. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.4269\/ajtmh.14-0553","article-title":"Inhibition of Cytochrome Bc1 as a Strategy for Single-Dose, Multi-Stage Antimalarial Therapy","volume":"92","author":"Stickles","year":"2015","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1128\/AAC.04149-14","article-title":"Subtle Changes in Endochin-like Quinolone Structure Alter the Site of Inhibition within the Cytochrome Bc1 Complex of Plasmodium Falciparum","volume":"59","author":"Stickles","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1039\/C1MD00183C","article-title":"The Development of Quinolone Esters as Novel Antimalarial Agents Targeting the Plasmodium Falciparum Bc1 Protein Complex","volume":"3","author":"Cowley","year":"2012","journal-title":"Medchemcomm"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"12244","DOI":"10.1021\/acs.joc.5b02169","article-title":"Quinolone-Hydroxyquinoline Tautomerism in Quinolone 3-Esters. Preserving the 4-Oxoquinoline Structure To Retain Antimalarial Activity","volume":"80","author":"Horta","year":"2015","journal-title":"J. Org. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/1873-3468.13035","article-title":"The Antimalarial Compound ELQ-400 Is an Unusual Inhibitor of the Bc 1 Complex, Targeting Both Q o and Q i Sites","volume":"592","author":"Song","year":"2018","journal-title":"FEBS Lett."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1128\/AAC.44.10.2771-2776.2000","article-title":"Anti-Toxoplasma Activities of 24 Quinolones and Fluoroquinolones in Vitro: Prediction of Activity by Molecular Topology and Virtual Computational Techniques","volume":"44","author":"Gozalbes","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1126\/science.3887571","article-title":"Qinghaosu (Artemisinin): An Antimalarial Drug from China","volume":"228","author":"Klayman","year":"1985","journal-title":"Science"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0020-7519(02)00194-7","article-title":"Artemisinin: Mechanisms of Action, Resistance and Toxicity","volume":"32","author":"Meshnick","year":"2002","journal-title":"Int. J. Parasitol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1128\/mr.60.2.301-315.1996","article-title":"Artemisinin and the Antimalarial Endoperoxides: From Herbal Remedy to Targeted Chemotherapy","volume":"60","author":"Meshnick","year":"1996","journal-title":"Microbiol. Rev."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"5032","DOI":"10.1128\/AAC.00298-15","article-title":"In Vitro Susceptibility of Leishmania Infantum to Artemisinin Derivatives and Selected Trioxolanes","volume":"59","author":"Cortes","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12936-018-2281-x","article-title":"New Endoperoxides Highly Active in Vivo and in Vitro against Artemisinin-Resistant Plasmodium Falciparum","volume":"17","author":"Lobo","year":"2018","journal-title":"Malar. J."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1021\/acsinfecdis.9b00257","article-title":"Ozonide Antimalarials Alkylate Heme in the Malaria Parasite Plasmodium Falciparum","volume":"5","author":"Giannangelo","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s40265-018-0911-9","article-title":"Drugs in Development for Malaria","volume":"78","author":"Ashley","year":"2018","journal-title":"Drugs"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1016\/j.bmcl.2009.02.013","article-title":"Semi-Synthetic and Synthetic 1,2,4-Trioxaquines and 1,2,4-Trioxolaquines: Synthesis, Preliminary SAR and Comparison with Acridine Endoperoxide Conjugates","volume":"19","author":"Barton","year":"2009","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1645\/13-451.1","article-title":"A Thiazole Derivative of Artemisinin Moderately Reduces Toxoplasma Gondii Cyst Burden in Infected Mice","volume":"100","author":"Schultz","year":"2014","journal-title":"J. Parasitol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"103467","DOI":"10.1016\/j.bioorg.2019.103467","article-title":"Synthesis, in Vitro and in Vivo Biological Evaluation of Dihydroartemisinin Derivatives with Potential Anti-Toxoplasma Gondii Agents","volume":"94","author":"Deng","year":"2019","journal-title":"Bioorg. Chem."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1128\/AAC.00502-09","article-title":"Artemisone and Artemiside Control Acute and Reactivated Toxoplasmosis in a Murine Model","volume":"53","author":"Dunay","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/jac\/dkn451","article-title":"Artemisinin Derivatives Inhibit Toxoplasma Gondii in Vitro at Multiple Steps in the Lytic Cycle","volume":"63","author":"Posner","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1128\/AAC.34.10.1961","article-title":"Inhibition of Growth of Toxoplasma Gondii by Qinghaosu and Derivatives","volume":"34","author":"Krug","year":"1990","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_71","first-page":"83","article-title":"Artesunate Effect on RH Virulent and ME49 Non-Virulent Strains of Toxoplasma Gondii: In Vitro and in Vivo Experimental Studies","volume":"17","author":"Mahmoud","year":"2016","journal-title":"Sci. Parasitol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.micinf.2004.09.002","article-title":"Artemisinins: Activities and Actions","volume":"6","author":"Haynes","year":"2004","journal-title":"Microbes Infect."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1128\/AAC.00582-07","article-title":"Artemisinin-Resistant Mutants of Toxoplasma Gondii Have Altered Calcium Homeostasis","volume":"51","author":"Nagamune","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.3390\/molecules15031705","article-title":"The Molecular Mechanism of Action of Artemisinin - The Debate Continues","volume":"15","author":"Barton","year":"2010","journal-title":"Molecules"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Secrieru, A., O\u2019Neill, P.M., and Cristiano, M.L.S. (2020). Revisiting the Structure and Chemistry of 3(5)-Substituted Pyrazoles. Molecules, 25.","DOI":"10.3390\/molecules25010042"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"5087","DOI":"10.1016\/j.bmc.2014.12.031","article-title":"Perspective: Challenges and Opportunities in TB Drug Discovery from Phenotypic Screening","volume":"23","author":"Manjunatha","year":"2015","journal-title":"Bioorganic Med. Chem."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"7240","DOI":"10.1016\/j.bmc.2015.10.021","article-title":"Aminopyrazolo[1,5-a]Pyrimidines as Potential Inhibitors of Mycobacterium Tuberculosis: Structure Activity Relationships and ADME Characterization","volume":"23","author":"Candice","year":"2015","journal-title":"Bioorganic Med. Chem."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Pinheiro, L.C.S., Feitosa, L.M., Gandi, M.O., Silveira, F.F., and Boechat, N. (2019). The Development of Novel Compounds against Malaria: Quinolines, Triazolpyridines, Pyrazolopyridines and Pyrazolopyrimidines. Molecules, 24.","DOI":"10.3390\/molecules24224095"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejmech.2016.09.073","article-title":"Evaluation of 7-Arylaminopyrazolo[1,5-a]Pyrimidines as Anti-Plasmodium Falciparum, Antimalarial, and Pf-Dihydroorotate Dehydrogenase Inhibitors","volume":"126","author":"Azeredo","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_80","unstructured":"Galarraga, E., Urdaneta, N., and Herrera, J.C. (2016, January 1\u201330). In Vitro Anti-Leishmanial and Anti-Trypanosomal Activity of Hydrazones, Pyrazoles, Pyrazolo[1,5-a]Pyrimidines and Pyrazolo[3,4-b]Pyridine, Synthesized from 6-Substituted-3-Formylchromones. Proceedings of the the 2nd International Electronic Conference on Medical Chemistry, Chemistry Department, Sim\u00f3n Bol\u00edvar University, Caracas, Venezuela. Available online: https:\/\/pdfs.semanticscholar.org\/d983\/af79e74b52e542975cbdc37f43949bb04814.pdf."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.00379-17","article-title":"Screening the Medicines for Malaria Venture Pathogen Box across Multiple Pathogens Reclassifies Starting Points for Open-Source Drug Discovery","volume":"61","author":"Duffy","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1016\/j.jmb.2018.12.015","article-title":"Peptide Design Principles for Antimicrobial Applications","volume":"431","author":"Torres","year":"2019","journal-title":"J. Molecular Biology."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fcimb.2016.00194","article-title":"Antimicrobial Peptides: An Emerging Category of Therapeutic Agents","volume":"6","author":"Mahlapuu","year":"2016","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_84","first-page":"3919","article-title":"The Antimicrobial Peptides and Their Potential Clinical Applications","volume":"11","author":"Lei","year":"2019","journal-title":"Am. J. Transl. Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2174\/0929866526666190925152957","article-title":"Clinical Applications of Antimicrobial Peptides (AMPs): Where Do We Stand Now?","volume":"27","author":"Divyashree","year":"2019","journal-title":"Protein Pept. Lett."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Sabi\u00e1 J\u00fanior, E.F., Menezes, L.F.S., de Ara\u00fajo, I.F.S., and Schwartz, E.F. (2019). Natural Occurrence in Venomous Arthropods of Antimicrobial Peptides Active against Protozoan Parasites. Toxins, 11.","DOI":"10.3390\/toxins11100563"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nchembio.1393","article-title":"Immune Modulation by Multifaceted Cationic Host Defense (Antimicrobial) Peptides","volume":"9","author":"Hilchie","year":"2013","journal-title":"Nat. Chem. Biol."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Fang, Y., He, X., Zhang, P., Shen, C., Mwangi, J., Xu, C., Mo, G., Lai, R., and Zhang, Z. (2019). In Vitro and In Vivo Antimalarial Activity of LZ1, a Peptide Derived from Snake Cathelicidin. Toxins, 11.","DOI":"10.3390\/toxins11070379"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3389\/fphar.2014.00275","article-title":"Antimicrobial Peptides: A New Class of Antimalarial Drugs?","volume":"5","author":"Vale","year":"2014","journal-title":"Front. Pharmacol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"205","DOI":"10.26444\/aaem\/74471","article-title":"Utilisation of Peptides against Microbial Infections \u2013 a Review","volume":"25","author":"Mirski","year":"2018","journal-title":"Ann. Agric. Environ. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.pt.2018.07.013","article-title":"Novel Defense Peptides from Platelets Kill Malaria Parasites","volume":"34","author":"Mather","year":"2018","journal-title":"Trends Parasitol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.2174\/138945012802002393","article-title":"Antimicrobial Peptide Action on Parasites","volume":"13","author":"Torrent","year":"2012","journal-title":"Curr. Drug Targets"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1471-4922(02)02428-5","article-title":"Antimicrobial Peptides versus Parasitic Infections?","volume":"18","author":"Vizioli","year":"2002","journal-title":"Trends Parasitol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.bbamem.2007.01.015","article-title":"Inhibition of Malaria Parasite Blood Stages by Tyrocidines, Membrane-Active Cyclic Peptide Antibiotics from Bacillus Brevis","volume":"1768","author":"Rautenbach","year":"2007","journal-title":"Biochim. Biophys. Acta - Biomembr."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0014-5793(00)01384-3","article-title":"Scorpine, an Anti-Malaria and Anti-Bacterial Agent Purified from Scorpion Venom","volume":"471","author":"Conde","year":"2001","journal-title":"FEBS Lett."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Prato, M. (2015). Human and Mosquito Lysozymes: Old Molecules for New Approaches against Malaria. Human and Mosquito Lysozymes, Springer.","DOI":"10.1007\/978-3-319-09432-8"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.4155\/fmc-2018-0460","article-title":"Antimicrobial Peptides with Antiprotozoal Activity: Current State and Future Perspectives","volume":"10","author":"Giovati","year":"2018","journal-title":"Future Med. Chem."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1007\/s00436-019-06305-x","article-title":"The Drosophila Melanogaster Antimicrobial Peptides Mtk-1 and Mtk-2 Are Active against the Malarial Parasite Plasmodium Falciparum","volume":"118","author":"Tonk","year":"2019","journal-title":"Parasitol. Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.ttbdis.2018.03.011","article-title":"Antiplasmodial Activity of Tick Defensins in a Mouse Model of Malaria","volume":"9","author":"Couto","year":"2018","journal-title":"Ticks Tick. Borne. Dis."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"De Le\u00f3n-Nava, M.A., Romero-N\u00fa\u00f1ez, E., Luna-Nophal, A., Bern\u00e1ldez-Sarabia, J., S\u00e1nchez-Campos, L.N., Licea-Navarro, A.F., Morales-Montor, J., and Mu\u00f1iz-Hern\u00e1ndez, S. (2016). In Vitro Effect of the Synthetic Cal14.1a Conotoxin, Derived from Conus Californicus, on the Human Parasite Toxoplasma Gondii. Mar. Drugs, 14.","DOI":"10.3390\/md14040066"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s11626-009-9271-9","article-title":"Parasiticidal Activity of Human \u03b1-Defensin-5 against Toxoplasma Gondii","volume":"46","author":"Tanaka","year":"2010","journal-title":"Vitr. Cell. Dev. Biol. Anim."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.peptides.2011.07.027","article-title":"Parasiticidal Activity of Haemaphysalis Longicornis Longicin P4 Peptide against Toxoplasma Gondii","volume":"34","author":"Tanaka","year":"2012","journal-title":"Peptides"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0167-7012(99)00117-7","article-title":"An Enzyme-Release Assay for the Assessment of the Lytic Activities of Complement or Antimicrobial Peptides on Extracellular Toxoplasma Gondii","volume":"39","author":"Seeber","year":"2000","journal-title":"J. Microbiol. Methods"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmicb.2018.00753","article-title":"Novel Activity of a Synthetic Decapeptide against Toxoplasma Gondii Tachyzoites","volume":"9","author":"Giovati","year":"2018","journal-title":"Front. Microbiol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/s12639-019-01113-7","article-title":"In Vitro Therapeutic Effect of Hemiscorpius Lepturus Venom on Tachyzoites of Toxoplasma Gondii","volume":"43","author":"Hamidinejat","year":"2019","journal-title":"J. Parasit. Dis."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/pim.12619","article-title":"Research on the Effect and Mechanism of Antimicrobial Peptides HPRP-A1\/A2 Work against Toxoplasma Gondii Infection","volume":"41","author":"Liu","year":"2019","journal-title":"Parasite Immunol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.toxicon.2019.05.003","article-title":"Anti-Toxoplasma Gondii Effect of Two Spider Venoms in Vitro and in Vivo","volume":"166","author":"Hou","year":"2019","journal-title":"Toxicon"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.26508\/lsa.201900549","article-title":"Initial Phospholipid-Dependent Irgb6 Targeting to Toxoplasma Gondii Vacuoles Mediates Host Defense","volume":"3","author":"Lee","year":"2020","journal-title":"Life Sci. Alliance"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.exppara.2019.01.009","article-title":"Anti-Parasitic Effect on Toxoplasma Gondii Induced by a Spider Peptide Lycosin-I","volume":"198","author":"Tang","year":"2019","journal-title":"Exp. Parasitol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.peptides.2019.02.002","article-title":"Fungi-Derived Lipopeptide Antibiotics Developed since 2000","volume":"113","author":"Zhao","year":"2019","journal-title":"Peptides"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s00726-014-1666-6","article-title":"Cyclodidepsipeptides with a Promising Scaffold in Medicinal Chemistry","volume":"46","author":"Smelcerovic","year":"2014","journal-title":"Amino Acids."},{"key":"ref_112","first-page":"766","article-title":"Metacytofilin Is a Potent Therapeutic Drug Candidate for Toxoplasmosis","volume":"221","author":"Leesombun","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/bs.adgen.2016.01.005","article-title":"Molecular Genetics of Secondary Chemistry in Metarhizium Fungi","volume":"Volume 94","author":"Raymond","year":"2016","journal-title":"Advances in Genetics"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.7164\/antibiotics.45.1553","article-title":"Metacytofilin, a Novel Immunomodulator Produced by Metarhizium Sp. TA2759","volume":"45","author":"Iijima","year":"1992","journal-title":"J. Antibiot."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/7\/1574\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:13:16Z","timestamp":1760173996000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/7\/1574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,30]]},"references-count":114,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,4]]}},"alternative-id":["molecules25071574"],"URL":"https:\/\/doi.org\/10.3390\/molecules25071574","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,30]]}}}